The NYT reports that new projections from the Bush administration show the Medicare drug plan costing about 10 percent less over the next decade than had previously been forecast. The article tells readers that the new projections will help support the Republicans' case that the drug plan should not be changed. (It may have been worth mentioning the Bush administration's history of manipulating these projections for political purposes.)
The last paragraph of the article cites Leslie V. Norwalk, the acting administrator of the Centers for Medicare and Medicaid Services, as saying that the cost is lower than expected both because drug prices are rising less rapidly than expected and "enrollment in the new Medicare program is lower than expected, because some beneficiaries found they had equivalent drug coverage from other sources."
Yes, the fact that many beneficiaries have decided that the Medicare drug program is not a good deal for them provides a good argument against changing it. What am I missing?
A second Trump administration will cement a right-wing majority on the Supreme Court for a generation, and put our collective future in the hands of someone who will be virtually unchecked by our institutions. The country has shifted rightward, and the reverberations will ensue for potentially the next few decades. In this climate, a robust independent media ecosystem will be more important than ever. We're committed to bringing you the latest news on how Trump's agenda will actually affect the American people, shining a light on the stories corporate media overlooks and keeping the public informed about how power really works in this country.
Quality journalism is expensive to produce, and we don't have corporate backers to rely on to fund what we do. Everything we do is thanks to our incredible community of readers, who chip in a few dollars at a time to make our work possible. Any amount you give today will help us continue reporting on what matters to our democracy.